Decoding colorectal cancer targeted therapy: a bibliometric journey of the last decade (2015-2024)

被引:0
作者
Zhou, Linpo [1 ]
Huang, Xuanwei [1 ]
Shi, Jing [1 ]
Yang, Yebin [1 ]
Dong, Fanhe [1 ]
Wei, Haoran [1 ]
Ji, Chenghao [1 ]
Shan, Yuqiang [2 ]
机构
[1] Zhejiang Chinese Med Univ, Hangzhou Peoples Hosp 1, Sch Clin Med 4, Hangzhou 310053, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Gastrointestinal Surg, Hangzhou 310006, Zhejiang, Peoples R China
关键词
Colorectal cancer (CRC); Targeted therapy; EGFR; RAS; Bibliometric analysis; Tumor microenvironment; Research trends; PROGRAMMED CELL-DEATH; WILD-TYPE; PLUS CETUXIMAB; BEVACIZUMAB; INHIBITION; CHEMOTHERAPY; COLON; GENE; EGFR; KRAS;
D O I
10.1007/s12672-025-02251-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer remains one of the most commonly diagnosed cancers globally, with a significant impact on public health. Targeted therapies have revolutionized the treatment landscape for colorectal cancer by offering increased specificity and reduced systemic toxicity compared to conventional chemotherapy. This study provides a comprehensive bibliometric analysis of global research on targeted therapy for colorectal cancer, focusing on publications from 2015 to 2024. A total of 3213 publications were retrieved from the Web of Science Core Collection and analyzed using bibliometric tools to construct knowledge maps and visualize research trends. The regression analysis shows a strong upward trend in publications from 2015 to 2024 (P < 0.001, R-2 = 0.889). China leads in publication output, with the University of Texas MD Anderson Cancer Center contributing the highest number of studies. Tabernero and Kopetz are the core authors in the field. Research in this domain has primarily concentrated on the development and clinical assessment of drugs targeting the EGFR, RAS, VEGF, and BRAF signaling pathways, as well as investigating the pathogenesis, drug resistance, and metastatic mechanisms of colorectal cancer. Current advancements emphasize Artificial Intelligence-driven multi-omics integration, the creation of novel therapeutics targeting established molecular pathways, and the execution of global clinical trials to validate personalized treatment strategies.
引用
收藏
页数:21
相关论文
共 67 条
[1]   The field-standardized average impact of national research systems compared to world average: the case of Italy [J].
Abramo, Giovanni ;
D'Angelo, Ciriaco Andrea ;
Viel, Fulvio .
SCIENTOMETRICS, 2011, 88 (02) :599-615
[2]   Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial [J].
Adams, Richard ;
Brown, Ewan ;
Brown, Louise ;
Butler, Rachel ;
Falk, Stephen ;
Fisher, David ;
Kaplan, Richard ;
Quirke, Phil ;
Richman, Susan ;
Samuel, Leslie ;
Seligmann, Jenny ;
Seymour, Matt ;
Shiu, Kai Keen ;
Wasan, Harpreet ;
Wilson, Richard ;
Maughan, Tim .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (03) :162-171
[3]   EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer [J].
Algars, Annika ;
Sundstrom, Jari ;
Lintunen, Minnamaija ;
Jokilehto, Terhi ;
Kytola, Soili ;
Kaare, Milja ;
Vainionpaa, Reetta ;
Orpana, Arto ;
Osterlund, Pia ;
Ristimaki, Ari ;
Carpen, Olli ;
Ristamaki, Raija .
INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) :922-929
[4]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[5]   Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].
Andre, T. ;
Shiu, K-K ;
Kim, T. W. ;
Jensen, B., V ;
Jensen, L. H. ;
Punt, C. ;
Smith, D. ;
Garcia-Carbonero, R. ;
Benavides, M. ;
Gibbs, P. ;
de la Fouchardiere, C. ;
Rivera, F. ;
Elez, E. ;
Bendell, J. ;
Le, D. T. ;
Yoshino, T. ;
Van Cutsem, E. ;
Yang, P. ;
Farooqui, M. Z. H. ;
Marinello, P. ;
Diaz, L. A., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218
[6]   Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models [J].
Aslam, Razia ;
Richards, Cathy E. ;
Fay, Joanna ;
Hudson, Lance ;
Workman, Julie ;
Lee, Cha Len ;
Murphy, Adrian ;
O'Neill, Brian ;
Toomey, Sinead ;
Hennessy, Bryan T. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
[7]  
Bakkalbasi Nisa, 2006, Biomed Digit Libr, V3, P7, DOI 10.1186/1742-5581-3-7
[8]   BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression [J].
Barras, David ;
Missiaglia, Edoardo ;
Wirapati, Pratyaksha ;
Sieber, Oliver M. ;
Jorissen, Robert N. ;
Love, Chris ;
Molloy, Peter L. ;
Jones, Ian T. ;
McLaughlin, Stephen ;
Gibbs, Peter ;
Guinney, Justin ;
Simon, Iris M. ;
Roth, Arnaud D. ;
Bosman, Fred T. ;
Tejpar, Sabine ;
Delorenzi, Mauro .
CLINICAL CANCER RESEARCH, 2017, 23 (01) :104-115
[9]   Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials [J].
Berger, M. D. ;
Stintzing, S. ;
Heinemann, V. ;
Yang, D. ;
Cao, S. ;
Sunakawa, Y. ;
Ning, Y. ;
Matsusaka, S. ;
Okazaki, S. ;
Miyamoto, Y. ;
Suenaga, M. ;
Schirripa, M. ;
Soni, S. ;
Zhang, W. ;
Falcone, A. ;
Loupakis, F. ;
Lenz, H-J .
ANNALS OF ONCOLOGY, 2017, 28 (11) :2780-2785
[10]   Web of Science as a data source for research on scientific and scholarly activity [J].
Birkle, Caroline ;
Pendlebury, David A. ;
Schnell, Joshua ;
Adams, Jonathan .
QUANTITATIVE SCIENCE STUDIES, 2020, 1 (01) :363-376